Alto Neuroscience Inc Dossier
Qualitative Analysis
Business overview
Alto Neuroscience, Inc. (NYSE: ANRO) is a clinical-stage biopharmaceutical company pioneering a precision psychiatry approach to redefine the treatment of neuropsychiatric disorders. By leveraging its proprietary Precision Psychiatry Platform™, Alto measures brain biomarkers through electroencephalography (EEG) activity, neurocognitive assessments, wearable data, and other factors to identify patient subtypes most likely to respond to its novel drug candidates. The company's clinical-stage pipeline targets major depressive disorder (MDD), treatment-resistant depression (TRD), bipolar depression (BPD), and schizophrenia.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Following the acquisition of ALTO-207, Alto is prioritizing its resources toward advancing this lead asset through a Phase 2b trial in 1H 2026 and a planned Phase 3 trial by early 2027, aiming for a potential NDA submission.
Expected impact: Establishes a potentially pivotal clinical path for a highly validated mechanism in a large, underserved psychiatric market.
Following Phase 2 proof-of-concept results where ALTO-101 did not achieve statistical significance on its primary EEG endpoint, Alto decided not to independently advance the asset in CIAS. Instead, the company is actively exploring strategic partnering opportunities for its newly developed modified-release oral formulation of ALTO-101.
Expected impact: Out-licensing or collaborating on ALTO-101 to capture non-dilutive funding and drive future value without independent capital expenditure.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of Chase Therapeutics added two Phase II assets to Alto's neurology pipeline: CTC-501 (renamed ALTO-207), a fixed-dose combination of pramipexole and ondansetron for treatment-resistant depression, and CTC-413 (renamed ALTO-208) for Parkinson's disease.
Financial impact: Terms included $1.75 million upfront and up to $71.5 million in potential future development and commercial milestones, with $41 million tied to commercial success.
Strategic Partnerships
Collaboration to develop ALTO-101 using MEDRx's proprietary transdermal delivery system (TDS) to mitigate gastrointestinal side effects and improve pharmacokinetics.
Terms: Includes development milestones and royalty obligations on future sales.